Literature DB >> 12438641

The CD154/CD40 interaction required for retrovirus-induced murine immunodeficiency syndrome is not mediated by upregulation of the CD80/CD86 costimulatory molecules.

Kathy A Green1, W James Cook, Arlene H Sharpe, William R Green.   

Abstract

C57BL/6 (B6) mice infected with LP-BM5 retroviruses develop disease, including an immunodeficiency similar to AIDS. This disease, murine AIDS (MAIDS), is inhibited by in vivo anti-CD154 monoclonal antibody treatment. The similar levels of insusceptibility of CD40(-/-) and CD154(-/-) B6 mice indicate that CD154/CD40 molecular interactions are required for MAIDS. CD4(+) T and B cells, respectively, provide the CD154 and CD40 expression needed for MAIDS induction. Here, the required CD154/CD40 interaction is shown to be independent of CD80 and CD86 expression: CD80/CD86(-/-) B6 mice develop MAIDS after LP-BM5 infection.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12438641      PMCID： PMC136728          DOI： 10.1128/jvi.76.24.13106-13110.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  The B7-CD28 superfamily.

Authors:  Arlene H Sharpe; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  B7 costimulation is critical for antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus.

Authors:  A J McAdam; E A Farkash; B E Gewurz; A H Sharpe
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  LICOS, a primordial costimulatory ligand?

Authors:  D Brodie; A V Collins; A Iaboni; J A Fennelly; L M Sparks; X N Xu; P A van der Merwe; S J Davis
Journal:  Curr Biol       Date:  2000-03-23       Impact factor: 10.834

4.  Characteristics of the cell populations involved in extra-thymic lymphosarcoma induced in C57BL/6 mice by RadLV-Rs.

Authors:  E Legrand; R Daculsi; J F Duplan
Journal:  Leuk Res       Date:  1981       Impact factor: 3.156

5.  Characterization of the CD154-positive and CD40-positive cellular subsets required for pathogenesis in retrovirus-induced murine immunodeficiency.

Authors:  K A Green; R J Noelle; B G Durell; W R Green
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Either B7 costimulation or IL-2 can elicit generation of primary alloreactive CTL.

Authors:  A J McAdam; B E Gewurz; E A Farkash; A H Sharpe
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

Review 7.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

Authors:  Beatriz M Carreno; Mary Collins
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

8.  B cell immunodeficiency fails to develop in CD4-deficient mice infected with BM5: murine AIDS as a multistep disease.

Authors:  D P Harris; S Koch; L M Mullen; S L Swain
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

9.  Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV).

Authors:  P K Pattengale; C R Taylor; P Twomey; S Hill; J Jonasson; T Beardsley; M Haas
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

10.  Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis.

Authors:  T T Chang; C Jabs; R A Sobel; V K Kuchroo; A H Sharpe
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307
View more
  10 in total

1.  Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?

Authors:  Wen Li; William R Green
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

2.  The role of CD4 T cells in the pathogenesis of murine AIDS.

Authors:  Wen Li; William R Green
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Role of a cytotoxic-T-lymphocyte epitope-defined, alternative gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome.

Authors:  Arti Gaur; William R Green
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Immunotherapy of murine retrovirus-induced acquired immunodeficiency by CD4 T regulatory cell depletion and PD-1 blockade.

Authors:  Wen Li; William R Green
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency.

Authors:  Kathy A Green; W James Cook; William R Green
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiency.

Authors:  Megan A O'Connor; Jennifer L Vella; William R Green
Journal:  J Gen Virol       Date:  2015-08-06       Impact factor: 3.891

7.  CD40-associated TRAF 6 signaling is required for disease induction in a retrovirus-induced murine immunodeficiency.

Authors:  Kathy A Green; Cory L Ahonen; W James Cook; William R Green
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome.

Authors:  Kathy A Green; Taku Okazaki; Tasuku Honjo; W James Cook; William R Green
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

9.  MAIDS resistance-associated gene expression patterns in secondary lymphoid organs.

Authors:  Suprawee Tepsuporn; Jedediah N Horwitt; George W Cobb; Sharon A Stranford
Journal:  Immunogenetics       Date:  2008-07-09       Impact factor: 2.846

10.  The role of indoleamine 2,3-dioxygenase in LP-BPM5 murine retroviral disease progression.

Authors:  Megan A O'Connor; William R Green
Journal:  Virol J       Date:  2013-05-17       Impact factor: 4.099
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.